In addition to the new non-physician, covered recipients for US CMS – many countries/US states/localities have different & evolving requirements and sometimes broader coverage. Our practice will continue to be In addition, it will continue to be our practice to collect event-related data for all participants (even staff and 3rd party attendees) since that data is pertinent to data accuracy. When in doubt (and there are always questions), cast a broader net!

Other key points:
· Onsite events will be under the microscope – costs per person, alcoholic beverages, attendees associated with multiple sessions, justification for onsite vs virtual.
· Data and trend analysis is important – especially as company attestors look at significant YoY differences associated with general & research payments, natures of payment, and dollars.
· Covid has affected us in many ways – including challenges associated with collecting and verifying sign in sheets or attendance records.
· “Consent” and compliance with GDPR continues to be a focus for the Europe – and we see shifts around the world toward additional reporting and diligence.
· It is anybody’s guess as to how disputes (very low in our experience) will be affected by changes in reporting requirements – additional covered recipients, changes in natures of payment, Medical Device identification, etc.
· Formalized risk assessment should be considered – fed by “best available” data including Transparency Reporting.

As a sponsor of the event, we were gratified to hear experts and industry representatives share their learnings and speak about the future. Questions and in-session polling contributed to the dynamic aspect of the conference despite the virtual format. However, we are all looking forward to a time when we can come together safely in-person and enhance the experience!